Effect of intranasal immunization with inactivated avian influenza virus on local and systemic immune responses in ducks

Poultry Science

Volumn 91, Issue 5, 2012, Pages 1074-1080

  Kang, H ^a   Wang, H ^a   Yu, Q ^a   Yang, Q ^a  

^a NANJING AGRICULTURAL UNIVERSITY   (China)

Author keywords

CpG DNA; Inactivated avian influenza virus; Intranasal immunization; Respiratory tract; Sodium cholate

Indexed keywords

ANAS; AVES; AVIAN INFLUENZA VIRUS;

EID: 84859732359     PISSN: 00325791     EISSN: 15253171     Source Type: Journal    
DOI: 10.3382/ps.2011-01817     Document Type: Article

References (32)

1. Alexander, D. J. 2000. A review of avian influenza in different bird species. Vet. Microbiol. 74:3-13.
2. Baaten, B. J., B. Clarke, P. Strong, and S. Hou. 2010. Nasal mucosal administration of chitin microparticles boosts innate immunity against influenza A virus in the local pulmonary tissue. Vaccine 28:4130-4137.
3. Chen, H., G. J. Smith, S. Y. Zhang, K. Qin, J. Wang, K. S. Li, R. G. Webster, J. S. Peiris, and Y. Guan. 2005. Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature 436:191-192.
4. Chiou, C. J., L. P. Tseng, M. C. Deng, P. R. Jiang, S. L. Tasi, T. W. Chung, Y. Y. Huang, and D. Z. Liu. 2009. Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens. Biomaterials 30:5862-5868.
5. Chu, R. S., O. S. Targoni, A. M. Krieg, P. V. Lehmann, and C. V. Harding. 1997. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186:1623-1631.
6. Couch, R. B., R. L. Atmar, T. R. Cate, J. M. Quarles, W. A. Keitel, and N. H. Arden. 2009. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine 27:5344-5348.
7. Heike Weighardt, C. F., M. Veit, M. Rump, H. Wagner, and B. Holzmann. 2000. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J. Immunol. 168:4537-4543.
8. Ichinohe, T., A. Ainai, M. Tashiro, T. Sata, and H. Hasegawa. 2009. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 27:6276-6279.
9. Kryczek, I., S. Wei, L. Vatan, J. Escara-Wilke, W. Szeliga, E. T. Keller, and W. Zou. 2007. Cutting edge: Opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J. Immunol. 179:1423-1426.
10. Klinman, D. M. 2004. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4:249-258.
11. Kwant, A., and K. L. Rosenthal. 2004. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22:3098-3104.
12. Lin-lin, Z. X.-L. 2007. A simple protocol for genomic DNA extraction from human intestinal microflora. J. Xinjiang Medical University 30:722-724.
13. Liu, Y.-Z., J.-F. Zhang, and Y.-M. Gu. 2005. Immunogenicity evaluation of an inactivated H9 subtype avian influenza vaccine in ducks. Jiangsu J. Agric. Sci. 21:316-321.
14. Macpherson, A. J., K. D. McCoy, F. E. Johansen, and P. Brandtzaeg. 2008. The immune geography of IgA induction and function. Mucosal Immunol. 1:11-22.
15. Min, W., H. S. Lillehoj, J. Burnside, K. C. Weining, P. Staeheli, and J. J. Zhu. 2001. Adjuvant effects of IL-1beta, IL-2, IL-8, IL-15, IFN-alpha, IFN-gamma TGF-beta4, and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine 20:267-274.
16. Prabakaran, M., S. Velumani, F. He, A. K. Karuppannan, G. Y. Geng, L. K. Yin, and J. Kwang. 2008. Protective immunity against influenza H5N1 virus challenge in mice by intranasal coadministration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant. Virology 380:412-420.
17. Qian, Z. 2009. Effects of different mucosal immune adjuvants on dendritic cells, MHC II molecule, and nuclear factor-κB. Immunol. J. 25:524-528.
18. Ramsay, A. J., A. J. Husband, I. A. Ramshaw, S. Bao, K. I. Matthaei, G. Koehler, and M. Kopf. 1994. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 264:561-563.
19. Rauw, F., Y. Gardin, V. Palya, S. Anbari, M. Gonze, S. Lemaire, T. van den Berg, and B. Lambrecht. 2010. The positive adjuvant effect of chitosan on antigen-specific cell-mediated immunity after chickens vaccination with live Newcastle disease vaccine. Vet. Immunol. Immunopathol. 134:249-258.
20. Reemers, S. S., C. Jansen, M. J. Koerkamp, D. van Haarlem, P. van de Haar, W. G. Degen, W. van Eden, and L. Vervelde. 2010. Reduced immune reaction prevents immunopathology after challenge with avian influenza virus: A transcriptomics analysis of adjuvanted vaccines. Vaccine 28:6351-6360.
21. Sabbatini, F., A. Bandera, G. Ferrario, D. Trabattoni, G. Marchetti, F. Franzetti, M. Clerici, and A. Gori. 2010. Qualitative immune modulation by interleukin-2 (IL-2) adjuvant therapy in immunological nonresponder HIV-infected patients. PLoS ONE 5:e14119.
22. Sakaguchi, M., H. Nakamura, K. Sonoda, H. Okamura, K. Yokogawa, K. Matsuo, and K. Hira. 1998. Protection of chickens with or without maternal antibodies against both Marek's and Newcastle diseases by one-time vaccination with recombinant vaccine of Marek's disease virus type 1. Vaccine 16:472-479.
23. Sawicki, W. 2001. Penetration of verapamil hydrochloride in the presence of sodium glycocholate as penetration enhancer through mucous membrane. Pharmazie 56:74-77.
24. Scheerlinck, J. P., S. Gekas, H. H. Yen, S. Edwards, M. Pearse, A. Coulter, and P. Sutton. 2006. Local immune responses following nasal delivery of an adjuvanted influenza vaccine. Vaccine 24:3929-3936.
25. Siegrist, C. A. 2003. Mechanisms by which maternal antibodies influence infant vaccine responses: Review of hypotheses and definition of main determinants. Vaccine 21:3406-3412.
26. Stallknecht, D. E., and S. M. Shane. 1988. Host range of avian influenza virus in free-living birds. Vet. Res. Commun. 12:125-141.
27. Tamura, S., Y. Samegai, H. Kurata, T. Nagamine, C. Aizawa, and T. Kurata. 1988. Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. Vaccine 6:409-413.
28. Tseng, L. P., C. J. Chiou, C. C. Chen, M. C. Deng, T. W. Chung, Y. Y. Huang, and D. Z. Liu. 2009. Effect of lipopolysaccharide on intranasal administration of liposomal Newcastle disease virus vaccine to SPF chickens. Vet. Immunol. Immunopathol. 131:285-289.
29. WHO. 2002. Pages 28-39 in WHO manual on animal influenza diagnosis and surveillance. World Health Organization, Geneva, Switzerland.
30. Xiaowen, Z., Y. Qinghua, Z. Xiaofei, and Y. Qian. 2009. Co-administration of inactivated avian influenza virus with CpG or rIL-2 strongly enhances the local immune response after intranasal immunization in chicken. Vaccine 27:5628-5632.
31. Yang, P., C. Tang, D. Luo, Z. Zhan, L. Xing, Y. Duan, W. Jia, D. Peng, X. Liu, and X. Wang. 2010. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine. Vet. Microbiol. 146:17-23.
32. Zuercher, A. W. 2003. Upper respiratory tract immunity. Viral Immunol. 16:279-289.